New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients-Reference-Cited by-同舟云学术

New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients

Published:2019-10-07 Issue:10 Volume:14 Page:e0222762
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Bellin Annachiara^ORCID,Berto Patrizia,Themistoclakis Sakis,Chandak Aastha,Giusti Pietro^ORCID,Cavalli Giacomo,Bakshi Sumeet,Tessarin Michele,Deambrosis Paola,Chinellato Alessandro

Funder

LASER ANALYTICA

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference28 articles.

1. The global burden of atrial fibrillation and stroke: A systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe;GYH Lip;Chest,2012

2. Sanità, Istituto Superiore di. Il Progetto Cuore. Progetto cuore.iss. [Online] 02 11 2018. http://www.cuore.iss.it/.

3. Inzitari D, Polizzi BM, Roti L, Il Progetto FAI: La Fibrillazione Atriale in Italia. La Medicina di Iniziativa e il Medico di Medicina Generale per garantire l’accesso a servizi e cure efficaci riducendo i costi per il SSN e i costi sociali legati all’elevato rischio di ictus cerebrale. 2017.

4. Contemporary Burden of Atrial Fibrillation and Associated Mortality in Northeastern Italy;U Fedeli;American Journal of Cardiology,2016

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison between non-vitamin K oral antagonist versus warfarin in atrial fibrillation with and without valvular heart disease: a systematic review and meta-analysis;The Egyptian Heart Journal;2024-08-09

2. Population cost analysis of direct oral anticoagulants versus vitamin K antagonists for managing nonvalvular atrial fibrillation;2024-05-17

3. Prescribing patterns of new oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: A narrative review;Ukrainian Journal of Nephrology and Dialysis;2023-09-14

4. Gross Hematuria Associated with Anticoagulants and Antiplatelet Drugs: Analysis of Current Treatment Standards and Relevance of Co-medication and Pharmacological Interactions;European Urology Focus;2023-09

5. Quality-by-Design-Based Development of Rivaroxaban-Loaded Liquisolid Compact Tablets with Improved Biopharmaceutical Attributes;AAPS PharmSciTech;2023-08-28